Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

NCT01340209

Last updated date
Study Location
205.464.81020 Boehringer Ingelheim Investigational Site
Asahikawa, Hokkaido, , , Japan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. All patients including the patients under age (under 20 years old) must sign and date an Informed Consent Form consistent with ICH-GCP guidelines and Good Clinical Practice (GCP) prior to participation in the trial [i.e. prior to any trial procedures, including any pre-trial washout of medications and medication restrictions for pulmonary function test (PFT) at Visit 1]. Regarding patients under age, a guardian or a legally authorised representative must also sign and date an Informed Consent Form.

2. Male or female outpatients aged at least 18 years but not more than 75 years at Visit 0.

3. All patients must have at least a 12-week history of asthma at the time of enrolment (Visit 0) into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling inclusion criterion 5.

4. The initial diagnosis of asthma must have been made before the patient's age of 40.

5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator reversibility (15-30 minutes after 400 µg salbutamol) resulting in a Forced Expiratory Volume in one second (FEV1) increase of at least 12% and at least 200 mL .

6. All patients must have been on maintenance treatment with a medium, stable dose of inhaled corticosteroids (ICS) [alone or in a fixed combination with a Long-acting beta-adrenergic (LABA)] for at least 4 weeks prior to Visit 1.

7. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of at least 1.5.

8. All patients must have a pre-bronchodilator FEV1 at least 60% and less than or equal to 90% of predicted normal at Visit 1.

9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year (52 weeks) prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack years.

10. Patients must be able to use the Respimat inhaler correctly, which is judged at the discretion of the investigator..

11. Patients must be able to perform all trial related procedures including technically acceptable PFTs and use of electronic diary (eDiary)/peak flow meter, which is judged at the discretion of the investigator.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patients with a significant disease other than asthma. A significant disease is
defined as a disease which, in the opinion of the investigator, may (i) put the
patient at risk because of participation in the trial, or (ii) influence the results
of the trial, or (iii) cause concern regarding the patient's ability to participate in
the trial.


2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood
chemistry if the abnormality defines a significant disease as defined in exclusion
criterion no 1.


3. Patients with a recent history (i.e. 6 months or less) of myocardial infarction prior
to Visit 0.


4. Patients who have been hospitalised for cardiac failure during the past year prior to
Visit 0.


5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
arrhythmia requiring intervention or a change in drug therapy within the past year
prior to Visit 0.


6. Patients with lung diseases other than asthma (e.g. COPD).


7. Patients with known active tuberculosis.


8. Patients with malignancy and/or patients who have undergone resection, radiation
therapy or chemotherapy for malignancy within the last 5 years prior to Visit 0.
Patients with treated basal cell carcinoma are allowed.


9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
history of thoracotomy for other reasons should be evaluated as per exclusion
criterion no. 1.


10. Patients with significant alcohol or drug abuse, which is judged at the discretion of
the investigator, within the past 2 years prior to Visit 0.


11. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride
(BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the study
medication delivery systems.


12. Pregnant or nursing women.


13. Women of childbearing potential not using a highly effective method of birth control.


14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.


15. Patients who have been treated with beta-blocker medication within four weeks prior to
Visit 1 and/or during the screening period. Topical cardio-selective beta-blocker eye
medications for non-narrow angle glaucoma are allowed.


16. Patients who have been treated with the long-acting anticholinergic tiotropium
(Spiriva) within four weeks prior to Visit 1 and/or during the screening period.


17. Patients who have been treated with oral beta-adrenergics within four weeks prior to
Visit 1 and/or during the Screening period.


18. Patients who have been treated with systemic corticosteroids within four weeks prior
to Visit 1 and/or during the screening period.


19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®),
within 6 months prior to Visit 1 and/or during the screening period.


20. Patients who have been treated with other non-approved and according to international
guidelines not recommended "experimental" drugs for routine asthma therapy within four
weeks prior to Visit 1 and/or during the screening period.


21. Patients with any asthma exacerbation or any respiratory tract infection in the four
weeks prior to Visit 1 and/or during the screening period.


22. Patients who are currently participating in another trial.


23. Patients with narrow-angle glaucoma and/or micturition disorder due to prostatic
hyperplasia.


24. Patients with below 80% of the eDiary completion compliance on Visit 2 (diary
compliance of at least 80% is required).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaEfficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680
  1. Denver, Colorado
  2. Columbia, Missouri
  3. Warrensburg, Missouri
  4. Boys Town, Nebraska
  5. Canton, Ohio
  6. Koblenz,
  7. Rosenheim,
  8. Wesel,
  9. Balvi,
  10. Daugavpils,
  11. Rezekne,
  12. Riga,
  13. Riga,
  14. Vilnius,
  15. Vilnius,
  16. Vilnius,
  17. Kamnik,
  18. Ljubljana,
  19. Maribor,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
AsthmaRandomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284
  1. Hallein,
  2. Linz,
  3. Neumarkt am Wallersee,
  4. Schlüsslberg,
  5. Thalheim bei Wels,
  6. Berlin,
  7. Berlin,
  8. Frankfurt,
  9. Hamburg,
  10. Hannover,
  11. Mainz,
  12. Schwerin,
  13. Wiesbaden,
  14. Wiesloch,
  15. Ivano-Frankivsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kiev,
  19. Kiev,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEvaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
NCT00776984
  1. Fountain Valley, California
  2. Fresno, California
  3. Stockton, California
  4. Waterbury, Connecticut
  5. Pensacola, Florida
  6. Chicago, Illinois
  7. Normal, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Omaha, Nebraska
  11. Ocean, New Jersey
  12. Albany, New York
  13. Great Neck, New York
  14. Rockville Centre, New York
  15. High Point, North Carolina
  16. Canton, Ohio
  17. Upland, Pennsylvania
  18. Richmond, Virginia
  19. Concord, New South Wales
  20. Mississauga, Ontario
  21. Ottawa, Ontario
  22. Montreal, Quebec
  23. Aalborg,
  24. Aarhus C,
  25. Berlin,
  26. Hamburg,
  27. Lübeck,
  28. Rüdersdorf,
  29. Weinheim,
  30. Bussolengo (vr),
  31. Milano,
  32. Pavia,
  33. Pietra Ligure (sv),
  34. Himeji, Hyogo,
  35. Hiroshima, Hiroshima,
  36. Itabashi-ku, Tokyo,
  37. Kagoshima, Kagoshima,
  38. Kishiwada, Osaka,
  39. Kitakyusyu, Fukuoka,
  40. Koga, Fukuoka,
  41. Kurashiki, Okayama,
  42. Kurume, Fukuoka,
  43. Morioka, Iwate,
  44. Osaka-sayama, Osaka,
  45. Sendai, Miyagi,
  46. Seto, Aichi,
  47. Urasoe, Okinawa,
  48. Urasoe, Okinawa,
  49. Wakayama, Wakayama,
  50. Groningen,
  51. Leeuwarden,
  52. Schiedam,
  53. Auckland NZ,
  54. Christchurch,
  55. Newtown Wellington NZ,
  56. Tauranga,
  57. St. Petersburg,
  58. St. Petersburg,
  59. St. Petersburg,
  60. Belgrade,
  61. Nis,
  62. Sremska Kamenica,
  63. Bellville,
  64. Cape Town,
  65. Cape Town,
  66. Cape Town,
  67. Ankara,
  68. Ankara,
  69. Izmit,
  70. Kharkov,
  71. Kiev,
  72. Vinnytsya,
  73. Chertsey,
  74. Exeter,
  75. Windsor,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaA Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
NCT01152450
  1. Linz,
  2. Schlüsslberg,
  3. Thalheim bei Wels,
  4. Wels,
  5. Brno,
  6. Kyjov,
  7. Kohtla-Järve,
  8. Tallinn,
  9. Großhansdorf,
  10. Hannover,
  11. Mannheim,
  12. Schwerin,
  13. Daugavpils,
  14. Riga,
  15. Riga,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
Official Title  ICMJE A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma
Brief Summary The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat inhaler will be examined on top of maintenance treatment with inhaled corticosteroid controller medication in patients with moderate to severe persistent asthma. Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma exacerbations, effects on asthma control, and number of adverse events.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: Tiotropium Respimat
    Tiotropium high dose once daily delivered with Respimat inhaler
  • Drug: Placebo Respimat
    Tiotropium placebo once daily delivered with Respimat inhaler
  • Drug: Tiotropium Respimat
    Tiotropium low dose once daily delivered with Respimat inhaler
Study Arms  ICMJE
  • Experimental: Tiotropium Respimat (low dose)
    Tiotropium low dose once daily delivered with Respimat inhaler
    Intervention: Drug: Tiotropium Respimat
  • Experimental: Tiotropium Respimat (high dose)
    Tiotropium high dose once daily delivered with Respimat inhaler
    Intervention: Drug: Tiotropium Respimat
  • Placebo Comparator: Placebo Respimat
    Tiotropium placebo once daily delivered with Respimat inhaler
    Intervention: Drug: Placebo Respimat
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 6, 2013)
285
Original Estimated Enrollment  ICMJE
 (submitted: April 21, 2011)
280
Actual Study Completion Date  ICMJE April 2013
Actual Primary Completion Date April 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  1. All patients including the patients under age (under 20 years old) must sign and date an Informed Consent Form consistent with ICH-GCP guidelines and Good Clinical Practice (GCP) prior to participation in the trial [i.e. prior to any trial procedures, including any pre-trial washout of medications and medication restrictions for pulmonary function test (PFT) at Visit 1]. Regarding patients under age, a guardian or a legally authorised representative must also sign and date an Informed Consent Form.
  2. Male or female outpatients aged at least 18 years but not more than 75 years at Visit 0.
  3. All patients must have at least a 12-week history of asthma at the time of enrolment (Visit 0) into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling inclusion criterion 5.
  4. The initial diagnosis of asthma must have been made before the patient's age of 40.
  5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator reversibility (15-30 minutes after 400 µg salbutamol) resulting in a Forced Expiratory Volume in one second (FEV1) increase of at least 12% and at least 200 mL .
  6. All patients must have been on maintenance treatment with a medium, stable dose of inhaled corticosteroids (ICS) [alone or in a fixed combination with a Long-acting beta-adrenergic (LABA)] for at least 4 weeks prior to Visit 1.
  7. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of at least 1.5.
  8. All patients must have a pre-bronchodilator FEV1 at least 60% and less than or equal to 90% of predicted normal at Visit 1.
  9. Patients must be never-smokers or ex-smokers who stopped smoking at least one year (52 weeks) prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack years.
  10. Patients must be able to use the Respimat inhaler correctly, which is judged at the discretion of the investigator..
  11. Patients must be able to perform all trial related procedures including technically acceptable PFTs and use of electronic diary (eDiary)/peak flow meter, which is judged at the discretion of the investigator.

Exclusion criteria:

  1. Patients with a significant disease other than asthma. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
  2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood chemistry if the abnormality defines a significant disease as defined in exclusion criterion no 1.
  3. Patients with a recent history (i.e. 6 months or less) of myocardial infarction prior to Visit 0.
  4. Patients who have been hospitalised for cardiac failure during the past year prior to Visit 0.
  5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year prior to Visit 0.
  6. Patients with lung diseases other than asthma (e.g. COPD).
  7. Patients with known active tuberculosis.
  8. Patients with malignancy and/or patients who have undergone resection, radiation therapy or chemotherapy for malignancy within the last 5 years prior to Visit 0. Patients with treated basal cell carcinoma are allowed.
  9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 1.
  10. Patients with significant alcohol or drug abuse, which is judged at the discretion of the investigator, within the past 2 years prior to Visit 0.
  11. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the study medication delivery systems.
  12. Pregnant or nursing women.
  13. Women of childbearing potential not using a highly effective method of birth control.
  14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.
  15. Patients who have been treated with beta-blocker medication within four weeks prior to Visit 1 and/or during the screening period. Topical cardio-selective beta-blocker eye medications for non-narrow angle glaucoma are allowed.
  16. Patients who have been treated with the long-acting anticholinergic tiotropium (Spiriva) within four weeks prior to Visit 1 and/or during the screening period.
  17. Patients who have been treated with oral beta-adrenergics within four weeks prior to Visit 1 and/or during the Screening period.
  18. Patients who have been treated with systemic corticosteroids within four weeks prior to Visit 1 and/or during the screening period.
  19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®), within 6 months prior to Visit 1 and/or during the screening period.
  20. Patients who have been treated with other non-approved and according to international guidelines not recommended "experimental" drugs for routine asthma therapy within four weeks prior to Visit 1 and/or during the screening period.
  21. Patients with any asthma exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 and/or during the screening period.
  22. Patients who are currently participating in another trial.
  23. Patients with narrow-angle glaucoma and/or micturition disorder due to prostatic hyperplasia.
  24. Patients with below 80% of the eDiary completion compliance on Visit 2 (diary compliance of at least 80% is required).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01340209
Other Study ID Numbers  ICMJE 205.464
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Boehringer IngelheimBoehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP